AU Patent

AU2020203311A1 — Use of pilocarpine hydrochloride for the treatment of ocular conditions

Assigned to Allergan Inc · Expires 2020-06-11 · 6y expired

What this patent protects

USE OF PILOCARPINE HYDROCHLORIDE FOR THE TREATMENT OF OCULAR CONDITIONS Abstract Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formula…

USPTO Abstract

USE OF PILOCARPINE HYDROCHLORIDE FOR THE TREATMENT OF OCULAR CONDITIONS Abstract Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020203311A1
Jurisdiction
AU
Classification
—
Expires
2020-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.